Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The Red Sea strategy: What does Israel stand to gain from recognizing Somaliland? - 2Figure out How to Explore the Infotainment Framework in the Slam 1500.
- 3The Most Astonishing Arising Advances to Watch
- 4Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- 5Must-Have Wellness Gear: What to Purchase for Successful Exercises
- The most effective method to Pick the Best Material Organization: Insider Tips
- A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- Bavarian leader questions Germany's Eurovision participation
- Desired Travel Objections Worldwide: Where to Go Straightaway
- First SpaceX booster for upgraded Starship fails during test in Texas
- Best Streaming Gadget for Your Home Theater
- A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- 5 High Limit Outer Hard Drives For Information Stockpiling
